Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
weBiom is a South Korean biotechnology company established in 2021 as a joint venture between Ildong Holdings and the Korea Food Research Institute (KFRI). The company operates as a research institute enterprise focused on the commercialization of microbiome-based technologies for health functional foods and therapeutic applications. weBiom leverages a vast library of functional microbial strains to develop products targeting the gut-brain axis, metabolic health, and immune regulation. Their pipeline includes live biotherapeutic products (LBPs) for indications such as obesity and cognitive decline. By combining KFRI's research capabilities with Ildong's pharmaceutical manufacturing expertise, weBiom aims to lead the next generation of microbiome-derived health solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on weBiom, Korea Food Research Institute.